Additionally, post‐treatment hepatoblastoma patients displayed reduced IGF2 levels compared to their pre‐treatment counterparts, indicating that serum IGF2 levels could potentially serve as a biomarker for treatment response (Figure 8D). The gene discussed is IGF2; the disease is hepatoblastoma.